Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding dual specific phosphatase 6. Methods of using these compounds for modulation of dual specific phosphatase 6 expression and for treatment of diseases associated with expression of dual specific phosphatase 6 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of ROCK 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ROCK 1. Methods of using these compounds for modulation of ROCK 1 expression and for diagnosis and treatment of disease associated with expression of ROCK 1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of TEK. The compositions comprise oligonucleotides, targeted to nucleic acid encoding TEK. Methods of using these compounds for modulation of TEK expression and for diagnosis and treatment of disease associated with expression of TEK are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of PTPN13. The compositions comprise oligonucleotides, targeted to nucleic acid encoding PTPN13. Methods of using these compounds for modulation of PTPN13 expression and for diagnosis and treatment of disease associated with expression of PTPN13 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Talin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Talin. Methods of using these compounds for modulation of Talin expression and for treatment of diseases associated with expression of Talin are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of matrix metalloproteinase 11. The compositions comprise oligonucleotides, targeted to nucleic acid encoding matrix metalloproteinase 11. Methods of using these compounds for modulation of matrix metalloproteinase 11 expression and for diagnosis and treatment of disease associated with expression of matrix metalloproteinase 11 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTPN12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN12. Methods of using these compounds for modulation of PTPN12 expression and for treatment of diseases associated with expression of PTPN12 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3K p85. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3K p85. Methods of using these compounds for modulation of PI3K p85 expression and for treatment of diseases associated with expression of PI3K p85 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ubiquitin protein ligases WWP1 and WWP2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ubiquitin protein ligases WWP1 and WWP2. Methods of using these compounds for modulation of ubiquitin protein ligases WWP1 and WWP2 expression and for treatment of diseases associated with expression of ubiquitin protein ligases WWP1 and WWP2 are provided.

Abstract: Compositions and are provided which are targeted to nucleic acids methods are provided for the modulation of ras expression. Oligonucleotides encoding human ras. Oligonucleotides specifically hybridizable with mRNA encoding human H-ras, Ki-ras and N-ras are provided. Such oligonucleotides can be used for therapeutics and diagnostics as well as for research purposes. Methods are also disclosed for modulating ras gene expression in cells and tissues using the oligonucleotides provided, and for specific modulation of expression of activated ras. Methods for diagnosis, detection and treatment of conditions, or particular cancers, associated with ras are also disclosed.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CREB. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CREB. Methods of using these compounds for modulation of CREB expression and for treatment of diseases associated with expression of CREB are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTPRA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPRA. Methods of using these compounds for modulation of PTPRA expression and for treatment of diseases associated with expression of PTPRA are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTPRM. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPRM. Methods of using these compounds for modulation of PTPRM expression and for treatment of diseases associated with expression of PTPRM are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of protein kinase C-iota. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding protein kinase C-iota. Methods of using these compounds for modulation of protein kinase C-iota expression and for treatment of diseases associated with expression of protein kinase C-iota are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of LIM domain kinase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding LIM domain kinase 1. Methods of using these compounds for modulation of LIM domain kinase 1 expression and for treatment of diseases associated with expression of LIM domain kinase 1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding dual specific phosphatase 6. Methods of using these compounds for modulation of dual specific phosphatase 6 expression and for treatment of diseases associated with expression of dual specific phosphatase 6 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTPRK. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPRK. Methods of using these compounds for modulation of PTPRK expression and for treatment of diseases associated with expression of PTPRK are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTPN12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN12. Methods of using these compounds for modulation of PTPN12 expression and for treatment of diseases associated with expression of PTPN12 are provided.

Abstract: Iterative, preferably computer based iterative processes for generating synthetic compounds capable of modulation of target expression are provided. During iterations of the processes, a target nucleic acid sequence is provided or selected, and a library of candidate nucleobase sequences is generated in silico according to defined criteria. A “virtual” oligonucleotide chemistry is chosen and a library of virtual oligonucleotide compounds having the selected nucleobase sequences is generated. These virtual compounds are reviewed and compounds predicted to have particular properties are selected. The selected compounds are robotically synthesized and are preferably robotically assayed for a desired physical, chemical or biological activity. Compounds exhibiting the ability to modulate target expression are identified as target modulators.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of NF-kappa-B p65 subunit. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding NF-kappa-B p65 subunit. Methods of using these compounds for modulation of NF-kappa-B p65 subunit expression and for treatment of diseases associated with expression of NF-kappa-B p65 subunit are provided.